Hims & Hers will continue compounding semaglutide

I listened to Hims & Hers’ Q3 earnings call yesterday. A question was asked about continuing to compound when the shortage is over. Their response was that they customize dosages to help minimize side effects, so they will continue to compound, as this falls under the compounding rules.

It sounds like they intend to continue until they get a cease and desist letter from FDA. And then I expect them to challenge it legally. They have invested heavily in compounding pharmacies, and they had an amazing quarter. Revenue up 77% year over year.